Molecular Formula | C18H21BN2O3 |
Molar Mass | 324.18 |
Density | 1.16±0.1 g/cm3(Predicted) |
Boling Point | 414.1±25.0 °C(Predicted) |
pKa | 12.08±0.70(Predicted) |
Storage Condition | 2-8°C |
Introduction | N-(pyridin-2-yl)-4-(4,4,5,5-tetramethyl L-1,3, 2-dioxyborent-2-yl) carboxamide is an intermediate for the synthesis of the BTK inhibitor Acalabrutinib. On 31 October 2017, AstraZeneca's second-generation BTK inhibitor Acalabrutinib was approved by the FDA for marketing at an ultra-fast rate in patients with mantle cell lymphoma who had failed at least first-line previous treatment. |
Application | N-(pyridin-2-yl)-4-(4,4,5,5-tetramethyl L-1,3, 2-dioxyboron-2-yl) benzamide is an intermediate in organic synthesis and pharmaceutical intermediates, organic synthesis and pharmaceutical research and development process. |